| FLOX | FLOX + cetuximab |  | ||||
---|---|---|---|---|---|---|---|
H/H | H/R | R/R | H/H | H/R | R/R | Interaction P-value | |
KRAS wild-type (N = 273) | |||||||
Number of patients | N = 16 | N = 52 | N = 20 | N = 46 | N = 98 | N = 41 | Â |
Response | 63% (10/16) | 42% (22/52) | 45% (9/20) | 46% (21/46) | 51% (50/98) | 56% (23/41) | 0.27* |
PFS | 8.4 | 8.9 | 9.0 | 7.7 | 7.7 | 8.0 | 0.23†|
OS | 31.6 | 23.6 | 19.0 | 21.4 | 20.7 | 18.9 | 0.23†|
KRAS mutated (N = 169) | |||||||
Number of patients | N = 10 | N = 25 | N = 21 | N = 28 | N = 57 | N = 28 | Â |
Response | 60% (6/10) | 52% (13/25) | 19% (4/21) | 36% (10/28) | 46% (26/57) | 50% (14/28) | 0.04* |
PFS | 8.1 | 8.3 | 7.1 | 7.7 | 8.1 | 6.7 | 0.90†|
OS | 17.2 | 20.4 | 24.3 | 21.1 | 20.0 | 16.8 | 0.34†|
BRAF wild-type (N = 363) | |||||||
Number of patients | N = 22 | N = 62 | N = 34 | N = 58 | N = 130 | N = 57 | Â |
Response | 64% (14/22) | 48% (30/62) | 35% (12/34) | 47% (27/58) | 52% (68/130) | 54% (31/57) | 0.10* |
PFS | 9.3 | 8.9 | 7.7 | 8.5 | 8.1 | 8.0 | 0.47†|
OS | 31.6 | 23.8 | 21.5 | 21.9 | 21.5 | 17.6 | 0.93†|
BRAF mutated (N = 47) | |||||||
Number of patients | N =3 | N = 10 | N = 4 | N = 8 | N = 16 | N = 6 | Â |
Response | 33% (1/3) | 20% (2/10) | 0% (0/4) | 13% (1/8) | 25% (4/16) | 33% (2/6) | 0.72* |
PFS | 4.3 | 5.1 | 3.8 | 3.8 | 4.6 | 5.8 | 0.36†|
OS | 9.2 | 9.4 | 5.6 | 8.9 | 8.1 | 11.3 | 0.73†|